Biotech & pharma press releases — Press Release Database

AI · Biotech & pharma

Global Cell Line Generation Market Outlook, 2026-2032 - AI, CRISPR and Automation Fuel 10.86% CAGR, Driving the Market to USD 2.67 Billion as Thermo Fisher Scientific, Lonza, Merck and WuXi Biologics Advance Innovation

Boost ROI through standardized QC, auditable automation, validated AI, diversified reagent sourcing, regional partnerships, and cross-skilled workforce training Boost ROI through standardized QC, auditable automation, validated AI, diversified reagent sourcing, regional partnerships, and cross-skilled workforce training

Sep 28 · 09:03GlobeNewswire

Healthcare · Biotech & pharma

Lift Therapeutics Appoints Eva Ehrnrooth as Executive Head of Clinical Development and Adds Chau Khuong to Board of Directors

Lift Therapeutics today announced the appointment of Eva Ehrnrooth as Executive Head of Clinical Development and Chau Khuong to its Board of Directors.

Sep 28 · 09:00GlobeNewswire

AI · Biotech & pharma

Global Peptoids Market Forecast, 2026-2032 - AI-Enabled Discovery and Expanding Drug Delivery, Diagnostics, and Biomaterials Applications Drive 10.81% CAGR Toward USD 145.45 Million

Boost ROI by targeting validated applications, standardizing synthesis, using DOE and AI to prioritize R&D, partnering to close gaps, and addressing IP and regulation early. Boost ROI by targeting validated applications, standardizing synthesis, using DOE and AI to prioritize R&D, partnering to close gaps, and addressing IP and regulation early.

Sep 28 · 09:00GlobeNewswire

Finance · Biotech & pharma

ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY

NEW YORK, Sept. 28, 2026 -- The DJS Law Group reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ: SPRY) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by...

Sep 28 · 08:12PR Newswire

Finance · Biotech & pharma

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

LOS ANGELES, Sept. 28, 2026 -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ: SPRY) for violations of §§10(b) and 20(a) of the...

Sep 28 · 08:11PR Newswire

SaaS · Healthcare

SPORVIGILANCE Targets Safer Medicines and Billion-Euro Savings for Global Pharma Facing EU IDMP Fines

LONDON, September 28, 2026--British regulatory technology company SPORVIGILANCE is targeting one of global pharma’s major compliance challenges with a platform offering a faster route to IDMP and SPOR readiness, compliance and governance.

Sep 28 · 06:13Business Wire

Finance · Biotech & pharma

CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law

LOS ANGELES, Sept. 28, 2026 -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a)...

Sep 28 · 06:11PR Newswire

Finance · Biotech & pharma

Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR

NEW YORK, Sept. 28, 2026 -- The DJS Law Group reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated...

Sep 28 · 06:10PR Newswire

Biotech & pharma

SOLA Biosciences Japan Receives AMED Grant to Advance SOL-257, Innovative Gene Therapy Aiming to Restore TDP-43 Function for ALS Patients

TOKYO and BOSTON, Sept. 28, 2026 -- SOLA Biosciences Japan GK ("SOLA Japan"), the wholly owned Japanese subsidiary of Boston-based SOLA Biosciences Inc. (together, "SOLA"), announced that it has been awarded a grant of approximately 6 billion yen over five years by the Japan...

Sep 28 · 06:00PR Newswire

Finance · Healthcare

Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update

Daix (France), New York (New York, United States), September 28, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today reported its financial information for the first half of 2026, ended June 30, 2026, including its cash position, cash flows and revenues, and provided a corporate update.

Sep 28 · 06:00GlobeNewswire

Finance · Healthcare

QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel

GERMANTOWN, Md. & VENLO, Netherlands, September 28, 2026--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that U.S.

Sep 28 · 05:30Business Wire

Finance · Biotech & pharma

AARD DEADLINE: ROSEN, HIGHLY REGARDED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AARD

New York, New York--(September 27, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardvark's February 13, 2025 initial public offering ("IPO"); and/or (ii) securities between February 13, 2025 and May 14, 2026, both dates inclusive (the...

Sep 28 · 02:24Newsfile